Diabetes

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

June 25, 2021

DOI: 10.1056/NEJMoa2107519

Abstract

BACKGROUND

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Diabetes Care 2021 January 4

PMID: 33397768

DOI: 10.2337/dc20-1473

 

 

Abstract

Objective: To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin.

Actualización del diagnóstico de hiperglucemia gestacional durante la pandemia COVID-19

Endocrinología, Diabetes y Nutrición

Vol. 67. Núm. 8.

páginas 545-552 (Octubre 2020)

DOI: 10.1016/j.endinu.2020.05.002

Mercè Codina, Rosa Corcoy, María M. Goya, en representación del GEDE Consenso del Grupo Español de Diabetes y Embarazo (GEDE) 

DOCUMENTO DE CONSENSO